Overview

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The study is designed as a multicenter, double blind, parallel-group, placebo-controlled, randomized, event driven Phase II study of DTIC with or without bosentan as first-line treatment in patients with stage IV melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Actelion
Treatments:
Bosentan